Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Collagen biology and non‐invasive biomarkers of liver fibrosis
M.A. Karsdal, Samuel J. Daniels, Signe Holm Nielsen, et al.
Liver International (2020) Vol. 40, Iss. 4, pp. 736-750
Open Access | Times Cited: 159

Showing 1-25 of 159 citing articles:

A guide to the composition and functions of the extracellular matrix
Nikos K. Karamanos, Achilleas D. Theocharis, Zoi Piperigkou, et al.
FEBS Journal (2021) Vol. 288, Iss. 24, pp. 6850-6912
Open Access | Times Cited: 640
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Arun J. Sanyal, Lee M. Kaplan, Juan P. Frías, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 2037-2048
Open Access | Times Cited: 53
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Shuang Wang, Scott L. Friedman
Science Translational Medicine (2023) Vol. 15, Iss. 716
Open Access | Times Cited: 52
BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial
Eric Lawitz, Diane E. Shevell, Giridhar Tirucherai, et al.
Hepatology (2021) Vol. 75, Iss. 4, pp. 912-923
Open Access | Times Cited: 60
Mapping the cardiac vascular niche in heart failure
Fabian Peisker, Maurice Halder, James S. Nagai, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 59
ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD
Kathleen E. Corey, Rebecca Pitts, Michelle Lai, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 1, pp. 25-33
Open Access | Times Cited: 56
Macrophage‐specific FGF12 promotes liver fibrosis progression in mice
Santie Li, Bin Zhou, Mei Xue, et al.
Hepatology (2022) Vol. 77, Iss. 3, pp. 816-833
Closed Access | Times Cited: 41
Human amniotic mesenchymal stem cells-derived IGFBP-3, DKK-3, and DKK-1 attenuate liver fibrosis through inhibiting hepatic stellate cell activation by blocking Wnt/β-catenin signaling pathway in mice
Quanwen Liu, Yan-Min Ying, Jiaxin Zhou, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 38
Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial
Elizabeth A. Brown, Anne Minnich, Arun J. Sanyal, et al.
JHEP Reports (2023) Vol. 5, Iss. 4, pp. 100661-100661
Open Access | Times Cited: 28
Setanaxib, a first‐in‐class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo‐controlled, phase 2 trial
Pietro Invernizzi, Marco Carbone, David Jones, et al.
Liver International (2023) Vol. 43, Iss. 7, pp. 1507-1522
Open Access | Times Cited: 23
The impact of chronic Trimethylamine N-oxide administration on liver oxidative stress, inflammation, and fibrosis
Cristian Marius Florea, Radu Roșu, Remus Moldovan, et al.
Food and Chemical Toxicology (2024) Vol. 184, pp. 114429-114429
Closed Access | Times Cited: 15
The role of noninvasive biomarkers for monitoring cell injury in advanced liver fibrosis
Riccardo Righetti, Felice Cinque, Keyur Patel, et al.
Expert Review of Gastroenterology & Hepatology (2025), pp. 1-16
Closed Access | Times Cited: 1
The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease
James P. Hardwick, Byoung‐Joon Song, Paul Rote, et al.
Frontiers in Physiology (2025) Vol. 15
Open Access | Times Cited: 1
Hot and Cold Fibrosis: The Role of Serum Biomarkers to assess the Immune Mechanisms and ECM-Cell Interactions in Human Fibrosis
Andressa de Zawadzki, Diana Julie Leeming, Arun J. Sanyal, et al.
Journal of Hepatology (2025)
Open Access | Times Cited: 1
The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis
Manal F. Abdelmalek, Edgar D. Charles, Arun J. Sanyal, et al.
Contemporary Clinical Trials (2021) Vol. 104, pp. 106335-106335
Open Access | Times Cited: 54
LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis
Benjamin E. Decato, Diana Julie Leeming, Jannie Marie Bülow Sand, et al.
Respiratory Research (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 30
Influence of extracellular matrix composition on tumour cell behaviour in a biomimetic in vitro model for hepatocellular carcinoma
Carlemi Calitz, Jenny Rosenquist, Oliver Degerstedt, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 21
Reprogramming activated hepatic stellate cells by siRNA-loaded nanocarriers reverses liver fibrosis in mice
Mahmoud A. Younis, Yusuke Sato, Yaser Hosny Ali Elewa, et al.
Journal of Controlled Release (2023) Vol. 361, pp. 592-603
Open Access | Times Cited: 20
Targeting collagen homeostasis for the treatment of liver fibrosis: Opportunities and challenges
Theerut Luangmonkong, Warisara Parichatikanond, Peter Olinga
Biochemical Pharmacology (2023) Vol. 215, pp. 115740-115740
Open Access | Times Cited: 19
Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC
Ebru Boslem, Saskia Reibe, Rodrigo Carlessi, et al.
Science Advances (2023) Vol. 9, Iss. 37
Open Access | Times Cited: 19
Obeticholic acid-loaded exosomes attenuate liver fibrosis through dual targeting of the FXR signaling pathway and ECM remodeling
Arezou Azizsoltani, Behzad Hatami, Mohammad Reza Zali, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115777-115777
Open Access | Times Cited: 18
Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease
Alejandro Campos-Murguía, Astrid Ruiz‐Margáin, José A González-Regueiro, et al.
World Journal of Gastroenterology (2020) Vol. 26, Iss. 39, pp. 5919-5943
Open Access | Times Cited: 49
Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis
Diletta Overi, Guido Carpino, Antonio Franchitto, et al.
Cells (2020) Vol. 9, Iss. 3, pp. 590-590
Open Access | Times Cited: 47
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease
Benedikt Simbrunner, Ida Falk Villesen, Philipp Königshofer, et al.
Liver International (2022) Vol. 42, Iss. 11, pp. 2501-2512
Open Access | Times Cited: 27
Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types
Nicholas Willumsen, Christina Jensen, George Green, et al.
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 4
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top